DE NOVO LIPOGENESIS AND METABOLIC DISEASE
DE NOVO LIPOGENESIS AND METABOLIC DISEASE
批准号:
8290871
负责人:
Clay F. Semenkovich
金额:
$33.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-04-01 至 2016-04-30
关键词:
AdultAffectAffinityAgonistAnabolismBindingBiological AvailabilityBlood VesselsCell NucleusCell membraneCell physiologyCellsCharacteristicsCholineComplications of Diabetes MellitusDefectDiabetes MellitusDietDiseaseEatingEndotheliumEnzymesEquilibriumEthanolaminesFailureFatty AcidsFatty LiverFatty-acid synthaseFunctional disorderGenerationsGenesGoalsHealthHumanKnock-outLecithinLifeLigandsLipid BindingLipidsLiverLiver diseasesMediatingMediator of activation proteinMembraneMetabolic DiseasesMetabolismMissionModificationMolecular ChaperonesMolecular TargetMorbidity - disease rateMusMyocardial InfarctionNitric OxideNuclear ReceptorsNutritionalObesityObesity associated diseasePalmitatesPeripheral Vascular DiseasesPeroxisome Proliferator-Activated ReceptorsPhenotypePhosphorylation SitePhosphotransferasesPhysiologicalPhysiologyPlayPredispositionPrevalenceProteinsPublic HealthRoleSeriesSignal TransductionSiteSourceStrokeTestingTissuesUnited States National Institutes of HealthVascular Diseasesangiogenesiscomputerized data processingenzyme activityhuman NOS3 proteinimprovedlipid biosynthesislipid metabolismmembrane synthesismortalitynew therapeutic targetnovel strategiespalmitoylationphosphatidylcholine transfer proteinresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Fatty acid synthase (FAS) synthesizes palmitate and other fatty acids. In adults, FAS has not been thought to be physiologically important. This notion was challenged by our demonstration that FAS affects metabolism in several tissues by activating the nuclear receptor PPAR¿. In liver, FAS-dependent activation is mediated in part by a phosphatidylcholine species that serves as a PPAR¿ ligand. FAS also drives a PPAR¿- independent signaling process. Endothelial FAS deficiency results in vascular dysfunction caused by impaired palmitoylation of endothelial nitric oxide synthase (eNOS). Addition of palmitate, the direct product of FAS, does not restore defective PPAR¿ or eNOS signaling in the setting of FAS deficiency. Our findings suggest that FAS is compartmentalized within an integrated cassette generating signaling-competent lipids that could affect metabolic disease. The long-term objective of this application is to improve the health of people with diabetes and obesity by modulating FAS signaling functions. This project will test the hypothesis that FAS transmits physiological signals. These lipid signals are compartmentalized through discrete signaling nodes, chaperones, and covalent modification of FAS itself to impact metabolic disease. The specific aims are: 1. To implicate phosphatidylcholine transfer protein (PC-TP) as a chaperone involved in the binding of an FAS-dependent endogenous ligand for PPAR¿ in the nucleus by comparing PC-TP-associated lipid spectra using PC-TP purified from livers of control mice and liver-specific FAS-deficient mice. 2. To determine if mice with tissue-specific inactivation of CEPT1 (a putative node for FAS signaling) in the liver and at the endothelium have phenotypes that mimic those of mice with tissue-specific inactivation of FAS. 3. To identify FAS-interacting proteins potentially involved in directing FAS to distinct cellular compartments and compartmentalizing its enzymatic product to discrete signaling nodes. 4. To determine if nutritionally regulated phosphorylation sites as well as other covalent modifications in FAS mediate FAS enzyme activity and cellular physiology. By establishing compartmentalized FAS as a mediator of physiological signals, this project could improve human health by identifying novel therapeutic targets for a wide range of metabolic disorders associated with diabetes and obesity.
PUBLIC HEALTH RELEVANCE: Diabetes, obesity, and associated diseases including fatty liver, peripheral vascular disease, stroke, heart attack, and related complications are major public health problems. These disorders are increasing in prevalence and available therapies are suboptimal. Therefore, this application is relevant to public health and to the mission of the NIH. It has a goal of identifying and validating a series of molecular targets that could be modulated to treat liver disease and vascular disease, major sources of morbidity and mortality in people with diabetes and obesity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lipidation and Vascular Disease
-
批准号:10396073
-
项目类别:
-
资助金额:$39.38万
-
财政年份:2021
-
负责人:Clay F. Semenkovich
-
依托单位:
Lipidation and Vascular Disease
-
批准号:10602437
-
项目类别:
-
资助金额:$39.38万
-
财政年份:2021
-
负责人:Clay F. Semenkovich
-
依托单位:
Lipidation and Vascular Disease
-
批准号:10180573
-
项目类别:
-
资助金额:$39.38万
-
财政年份:2021
-
负责人:Clay F. Semenkovich
-
依托单位:
Diabetes and Related Metabolic Diseases
-
批准号:9429380
-
项目类别:
-
资助金额:$1.12万
-
财政年份:2017
-
负责人:Clay F. Semenkovich
-
依托单位:
GLUCOCORTICOID RECEPTOR POST-TRANSLATIONAL MODIFICATIONS IN INSULIN RESISTANCE
-
批准号:9980364
-
项目类别:
-
资助金额:$34.31万
-
财政年份:2016
-
负责人:Clay F. Semenkovich
-
依托单位:
MODULATING PHYSIOLOGIC EFFECTS OF PHOSPHOLIPID METABOLISM IN OBESITY AND DIABETES
-
批准号:8885119
-
项目类别:
-
资助金额:$42.4万
-
财政年份:2015
-
负责人:Clay F. Semenkovich
-
依托单位:
MODULATING PHYSIOLOGIC EFFECTS OF PHOSPHOLIPID METABOLISM IN OBESITY AND DIABETES
-
批准号:9221327
-
项目类别:
-
资助金额:$42.4万
-
财政年份:2015
-
负责人:Clay F. Semenkovich
-
依托单位:
MACROPHAGE FATTY-ACID SYNTHASE DEFICIENCY DECREASES DIET-INDUCED ATHEROSCLEROSIS
-
批准号:8361454
-
项目类别:
-
资助金额:$0.43万
-
财政年份:2011
-
负责人:Clay F. Semenkovich
-
依托单位:
Animal Model Research Core
-
批准号:8132691
-
项目类别:
-
资助金额:$14.53万
-
财政年份:2011
-
负责人:Clay F. Semenkovich
-
依托单位:
OBESITY, ADIPOGENESIS, AND LIPID LIGANDS
-
批准号:7855309
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2010
-
负责人:Clay F. Semenkovich
-
依托单位:
OBESITY, ADIPOGENESIS, AND LIPID LIGANDS
-
批准号:8245176
-
项目类别:
-
资助金额:$31.56万
-
财政年份:2010
-
负责人:Clay F. Semenkovich
-
依托单位:
OBESITY, ADIPOGENESIS, AND LIPID LIGANDS
-
批准号:8444588
-
项目类别:
-
资助金额:$30.46万
-
财政年份:2010
-
负责人:Clay F. Semenkovich
-
依托单位:
OBESITY, ADIPOGENESIS, AND LIPID LIGANDS
-
批准号:8061601
-
项目类别:
-
资助金额:$31.56万
-
财政年份:2010
-
负责人:Clay F. Semenkovich
-
依托单位:
DE NOVO LIPOGENESIS AND METABOLIC DISEASE
-
批准号:8845193
-
项目类别:
-
资助金额:$33.06万
-
财政年份:2007
-
负责人:Clay F. Semenkovich
-
依托单位:
DE NOVO LIPOGENESIS AND METABOLIC DISEASE
-
批准号:8459974
-
项目类别:
-
资助金额:$31.9万
-
财政年份:2007
-
负责人:Clay F. Semenkovich
-
依托单位:
CHLOROQUINE AND THE METABOLIC SYNDROME
-
批准号:7603335
-
项目类别:
-
资助金额:$0.28万
-
财政年份:2007
-
负责人:Clay F. Semenkovich
-
依托单位:
De Novo Lipogenesis and Metabolic Disease
-
批准号:7616691
-
项目类别:
-
资助金额:$30.54万
-
财政年份:2007
-
负责人:Clay F. Semenkovich
-
依托单位:
De Novo Lipogenesis and Metabolic Disease
-
批准号:7173988
-
项目类别:
-
资助金额:$31.19万
-
财政年份:2007
-
负责人:Clay F. Semenkovich
-
依托单位:
CHLOROQUINE AND THE METABOLIC SYNDROME
-
批准号:7377221
-
项目类别:
-
资助金额:$1.83万
-
财政年份:2006
-
负责人:Clay F. Semenkovich
-
依托单位:
SCCOR in Metabolic Syndrome and Vascular Disease
-
批准号:7622662
-
项目类别:
-
资助金额:$196.92万
-
财政年份:2006
-
负责人:Clay F. Semenkovich
-
依托单位:
海外基金